Mice treated with long-acting bupivacaine compared to controls after 42 days (IMAGE)
Caption
After finding that sensory nerves can launch the growth of unwanted bone in cartilage after childhood bone injuries and impede recovery, Aaron James, M.D., Ph.D., and pathologists from the James Lab at Johns Hopkins Medicine, found inhibiting this response with an FDA-approved nerve blocker showed preclinical benefits in mice. The image above, Figure 8D from the paper (p. 1202), shows a comparison of mice who were treated with long-acting bupivacaine compared to controls after 42 days. They found this nerve-blocking treatment resulted in up to a 60% reduction of the abnormal growth and provides proof-of-concept findings to support further research in this area.
Credit
Science Translational Medicine
Usage Restrictions
None
License
Original content